183 related articles for article (PubMed ID: 31856268)
1. Atovaquone is active against AML by upregulating the integrated stress pathway and suppressing oxidative phosphorylation.
Stevens AM; Xiang M; Heppler LN; Tošić I; Jiang K; Munoz JO; Gaikwad AS; Horton TM; Long X; Narayanan P; Seashore EL; Terrell MC; Rashid R; Krueger MJ; Mangubat-Medina AE; Ball ZT; Sumazin P; Walker SR; Hamada Y; Oyadomari S; Redell MS; Frank DA
Blood Adv; 2019 Dec; 3(24):4215-4227. PubMed ID: 31856268
[TBL] [Abstract][Full Text] [Related]
2. Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent.
Xiang M; Kim H; Ho VT; Walker SR; Bar-Natan M; Anahtar M; Liu S; Toniolo PA; Kroll Y; Jones N; Giaccone ZT; Heppler LN; Ye DQ; Marineau JJ; Shaw D; Bradner JE; Blonquist T; Neuberg D; Hetz C; Stone RM; Soiffer RJ; Frank DA
Blood; 2016 Oct; 128(14):1845-1853. PubMed ID: 27531676
[TBL] [Abstract][Full Text] [Related]
3. Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor.
Redell MS; Ruiz MJ; Alonzo TA; Gerbing RB; Tweardy DJ
Blood; 2011 May; 117(21):5701-9. PubMed ID: 21447830
[TBL] [Abstract][Full Text] [Related]
4. A synthetic cell-penetrating peptide derived from nuclear localization signal of EPS8 exerts anticancer activity against acute myeloid leukemia.
Chen Y; Xie X; Wu A; Wang L; Hu Y; Zhang H; Li Y
J Exp Clin Cancer Res; 2018 Jan; 37(1):12. PubMed ID: 29357910
[TBL] [Abstract][Full Text] [Related]
5. Oxidative phosphorylation inhibition induces anticancerous changes in therapy-resistant-acute myeloid leukemia patient cells.
Vitkevičienė A; Janulis V; Žučenka A; Borutinskaitė V; Kaupinis A; Valius M; Griškevičius L; Navakauskienė R
Mol Carcinog; 2019 Nov; 58(11):2008-2016. PubMed ID: 31385375
[TBL] [Abstract][Full Text] [Related]
6. ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies.
Ishizawa J; Kojima K; Chachad D; Ruvolo P; Ruvolo V; Jacamo RO; Borthakur G; Mu H; Zeng Z; Tabe Y; Allen JE; Wang Z; Ma W; Lee HC; Orlowski R; Sarbassov dos D; Lorenzi PL; Huang X; Neelapu SS; McDonnell T; Miranda RN; Wang M; Kantarjian H; Konopleva M; Davis RE; Andreeff M
Sci Signal; 2016 Feb; 9(415):ra17. PubMed ID: 26884599
[TBL] [Abstract][Full Text] [Related]
7. SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism.
Polak A; Bialopiotrowicz E; Krzymieniewska B; Wozniak J; Stojak M; Cybulska M; Kaniuga E; Mikula M; Jablonska E; Gorniak P; Noyszewska-Kania M; Szydlowski M; Piechna K; Piwocka K; Bugajski L; Lech-Maranda E; Barankiewicz J; Kolkowska-Lesniak A; Patkowska E; Glodkowska-Mrowka E; Baran N; Juszczynski P
Cell Death Dis; 2020 Nov; 11(11):956. PubMed ID: 33159047
[TBL] [Abstract][Full Text] [Related]
8. Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in
Jiang X; Mak PY; Mu H; Tao W; Mak DH; Kornblau S; Zhang Q; Ruvolo P; Burks JK; Zhang W; McQueen T; Pan R; Zhou H; Konopleva M; Cortes J; Liu Q; Andreeff M; Carter BZ
Clin Cancer Res; 2018 May; 24(10):2417-2429. PubMed ID: 29463558
[No Abstract] [Full Text] [Related]
9. Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells.
Cook AM; Li L; Ho Y; Lin A; Li L; Stein A; Forman S; Perrotti D; Jove R; Bhatia R
Blood; 2014 May; 123(18):2826-37. PubMed ID: 24668492
[TBL] [Abstract][Full Text] [Related]
10. Validation of atovaquone plasma levels by liquid chromatography-tandem mass spectrometry for therapeutic drug monitoring in pediatric patients.
Horvath TD; Poventud-Fuentes I; Olayinka L; James A; Haidacher SJ; Hoch KM; Stevens AM; Haag AM; Devaraj S
J Mass Spectrom Adv Clin Lab; 2022 Nov; 26():23-27. PubMed ID: 36388060
[TBL] [Abstract][Full Text] [Related]
11. Imipridone ONC212 activates orphan G protein-coupled receptor GPR132 and integrated stress response in acute myeloid leukemia.
Nii T; Prabhu VV; Ruvolo V; Madhukar N; Zhao R; Mu H; Heese L; Nishida Y; Kojima K; Garnett MJ; McDermott U; Benes CH; Charter N; Deacon S; Elemento O; Allen JE; Oster W; Stogniew M; Ishizawa J; Andreeff M
Leukemia; 2019 Dec; 33(12):2805-2816. PubMed ID: 31127149
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic FLT3-ITD supports autophagy via ATF4 in acute myeloid leukemia.
Heydt Q; Larrue C; Saland E; Bertoli S; Sarry JE; Besson A; Manenti S; Joffre C; Mansat-De Mas V
Oncogene; 2018 Feb; 37(6):787-797. PubMed ID: 29059168
[TBL] [Abstract][Full Text] [Related]
13. SNS-032 inhibits mTORC1/mTORC2 activity in acute myeloid leukemia cells and has synergistic activity with perifosine against Akt.
Meng H; Jin Y; Liu H; You L; Yang C; Yang X; Qian W
J Hematol Oncol; 2013 Feb; 6():18. PubMed ID: 23415012
[TBL] [Abstract][Full Text] [Related]
14. MiR-20a-5p functions as a potent tumor suppressor by targeting PPP6C in acute myeloid leukemia.
Bao F; Zhang L; Pei X; Lian C; Liu Y; Tan H; Lei P
PLoS One; 2021; 16(9):e0256995. PubMed ID: 34587164
[TBL] [Abstract][Full Text] [Related]
15. Involvement of p38 in signal switching from autophagy to apoptosis via the PERK/eIF2α/ATF4 axis in selenite-treated NB4 cells.
Jiang Q; Li F; Shi K; Wu P; An J; Yang Y; Xu C
Cell Death Dis; 2014 May; 5(5):e1270. PubMed ID: 24874742
[TBL] [Abstract][Full Text] [Related]
16. MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells.
Zeng Z; Wang RY; Qiu YH; Mak DH; Coombes K; Yoo SY; Zhang Q; Jessen K; Liu Y; Rommel C; Fruman DA; Kantarjian HM; Kornblau SM; Andreeff M; Konopleva M
Oncotarget; 2016 Aug; 7(34):55083-55097. PubMed ID: 27391151
[TBL] [Abstract][Full Text] [Related]
17. The thymidine dideoxynucleoside analog, alovudine, inhibits the mitochondrial DNA polymerase γ, impairs oxidative phosphorylation and promotes monocytic differentiation in acute myeloid leukemia.
Yehudai D; Liyanage SU; Hurren R; Rizoska B; Albertella M; Gronda M; Jeyaraju DV; Wang X; Barghout SH; MacLean N; Siriwardena TP; Jitkova Y; Targett-Adams P; Schimmer AD
Haematologica; 2019 May; 104(5):963-972. PubMed ID: 30573504
[TBL] [Abstract][Full Text] [Related]
18. BPR1J373, an Oral Multiple Tyrosine Kinase Inhibitor, Targets c-KIT for the Treatment of c-KIT-Driven Myeloid Leukemia.
Chen LT; Chen CT; Jiaang WT; Chen TY; Butterfield JH; Shih NY; Hsu JT; Lin HY; Lin SF; Tsai HJ
Mol Cancer Ther; 2016 Oct; 15(10):2323-2333. PubMed ID: 27512117
[TBL] [Abstract][Full Text] [Related]
19. The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression.
Harada M; Benito J; Yamamoto S; Kaur S; Arslan D; Ramirez S; Jacamo R; Platanias L; Matsushita H; Fujimura T; Kazuno S; Kojima K; Tabe Y; Konopleva M
Oncotarget; 2015 Nov; 6(35):37930-47. PubMed ID: 26473447
[TBL] [Abstract][Full Text] [Related]
20. Ceramide Analogue SACLAC Modulates Sphingolipid Levels and
Pearson JM; Tan SF; Sharma A; Annageldiyev C; Fox TE; Abad JL; Fabrias G; Desai D; Amin S; Wang HG; Cabot MC; Claxton DF; Kester M; Feith DJ; Loughran TP
Mol Cancer Res; 2020 Mar; 18(3):352-363. PubMed ID: 31744877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
